Summary
The product DECA 200, manufactured by Unique Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number UN55447, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis determined the presence of Nandrolone Decanoate at a concentration of 184.07 mg/ml, which is 7.97% below the labeled claim of 200 mg/ml, indicating slight underdosing.
The testing process began on 14 November 2022, with the sample received on 22 November 2022, and analysis completed on 27 November 2022. While the results indicate minor underdosing, careful evaluation of reseller-submitted samples is necessary to ensure reliability across all batches. Resellers may select specific batches that meet high standards, potentially affecting the consistency of the product in the market. Independent third-party testing remains crucial for comprehensive verification. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: DECA 200
- Active Ingredient: Nandrolone Decanoate
- Batch Number: UN55447
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #25873
- Testing Ordered: 14 November 2022
- Sample Received: 22 November 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 200 mg/ml (as stated on the label)
- Measured Concentration: 184.07 mg/ml
- Accuracy: 92.03% (7.97% below the label claim)
- Variance: -7.97%
Verification Details
- Verification URL: https://janoshik.com/tests/25873_ZEPAMYWCCB4G
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis highlights the slight underdosing of the tested product but requires careful scrutiny as it was submitted and funded by the reseller Opitropin.EU. Resellers often select the best-performing batches for testing, which might not accurately represent the consistency of products available to consumers. While Janoshik Analytical follows stringent testing protocols, further independent validation across multiple batches would enhance the reliability of these findings.
Conclusion
The analysis confirms that DECA 200 is slightly underdosed, with a measured concentration of 184.07 mg/ml, which is 7.97% below the labeled claim. While this batch maintains some level of quality control, additional testing is advised to ensure consistent dosing across the entire product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed decisions regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful insights when critically assessed alongside independent third-party results. Readers are encouraged to use this information responsibly.
